News and Events
- Biogen Idec reports top-line results from Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS) January 3, 2013
- Knopp Biosciences Announces Recruiting of Key Scientific Executives and Completion of Laboratory Expansion May 2, 2012
- Data from Phase 2 Study of dexpramipexole in ALS published in Nature Medicine December 21, 2011
- ALS Association of Western Pennsylvania to Honor Knopp Biosciences with Anne Lewis Humanitarian Award March 31, 2011
- Knopp Biosciences Announces Hiring of Suresh Khemani as VP of Commercial and Clinical Affairs December 30, 2010
- Biogen Idec and Knopp Biosciences announce enrollment of the First Patient in a Global Phase III Study of Dexpramipexole for ALS December 1, 2010
- Knopp Neurosciences Forms New Parent Company to Expand Operations and Mission November 14, 2010
- Biogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate August 18, 2010
- Knopp Neurosciences Presents Further Encouraging Trends in its Phase 2 Study of KNS-760704 (Dexpramipexole) in ALS April 16, 2010
- Knopp Neurosciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS December 9, 2009
- Knopp Neurosciences Receives FDA Fast Track Designation for KNS-760704 in ALS September 2, 2009
- Knopp Neurosciences to Present Phase 2 Results of KNS-760704 in ALS August 11, 2009
- Knopp Neurosciences Inc. Sponsors ALS Awareness Day at PNC Park May 3, 2009
- European Commission Awards Orphan Designation to KNS-760704 in ALS March 9, 2009